These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 10632815)

  • 1. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease.
    Majumdar SR; Gurwitz JH; Soumerai SB
    J Gen Intern Med; 1999 Dec; 14(12):711-7. PubMed ID: 10632815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to prescription guidelines and achievement of treatment goals among persons with coronary heart disease in Tromsø 7.
    Pedersen E; Garcia BH; Halvorsen KH; Eggen AE; Schirmer H; Waaseth M
    BMC Cardiovasc Disord; 2021 Jan; 21(1):44. PubMed ID: 33478404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whom are we treating with lipid-lowering drugs? Are we following the guidelines? Evidence from a population-based study: the Tromso study 2001.
    Hartz I; Eggen AE; Grimsgaard S; Skjold F; Njølstad I
    Eur J Clin Pharmacol; 2004 Nov; 60(9):643-9. PubMed ID: 15455181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Who receives lipid-lowering drugs: the effects of comorbidities and patient characteristics on treatment initiation.
    Yang CC; Jick SS; Testa MA
    Br J Clin Pharmacol; 2003 Mar; 55(3):288-98. PubMed ID: 12630980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective, noninterventional, uncontrolled, open-chart, pharmacoepidemiologic study of prescribing patterns for lipid-lowering drugs at a tertiary care teaching hospital in North India.
    Goyal P; Sharma G; Bal BS; Singh J; Singh J; Randhawa GK; Pandhi S; Sharma R
    Clin Ther; 2002 Dec; 24(12):2064-76. PubMed ID: 12581545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary prevention in a cardiology group practice and hospital setting after a heart-care initiative.
    LaBresh KA; Owen P; Alteri C; Reilly S; Albright PS; Hordes AR; Shaftel PA; Noonan TE; Stoukides CA; Kaul AF
    Am J Cardiol; 2000 Feb; 85(3A):23A-29A. PubMed ID: 10695704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with discharge lipid-lowering drug prescription in patients hospitalized for coronary artery disease (from the Get With the Guidelines database).
    Albert NM; Birtcher KK; Cannon CP; Goff DC; Mulgund J; Liang L; Fonarow GC
    Am J Cardiol; 2008 May; 101(9):1242-6. PubMed ID: 18435951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary prevention of coronary artery disease in contemporary clinical practice.
    Jankowski P; Czarnecka D; Wolfshaut-Wolak R; Łysek R; Łukaszewska A; Bogacki P; Grodecki J; Mirek-Bryniarska E; Nessler J; Podolec P; Kawecka-Jaszcz K; Pająk A
    Cardiol J; 2015; 22(2):219-26. PubMed ID: 25299500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discontinuation and switching of therapy after initiation of lipid-lowering drugs: the effects of comorbidities and patient characteristics.
    Yang CC; Jick SS; Testa MA
    Br J Clin Pharmacol; 2003 Jul; 56(1):84-91. PubMed ID: 12848779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of a targeted intervention on lipid-lowering therapy in patients with coronary artery disease in the hospital setting.
    Lacy CR; Suh DC; Barone JA; Bueno M; Moylan D; Swartz C; Kudipudi RV; Kostis JB
    Arch Intern Med; 2002 Feb; 162(4):468-73. PubMed ID: 11863482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study.
    García Ruiz FJ; Marín Ibáñez A; Pérez-Jiménez F; Pintó X; Nocea G; Ahumada C; Alemao E; Yin D;
    Pharmacoeconomics; 2004; 22 Suppl 3():1-12. PubMed ID: 15669149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid-lowering drug use and cardiovascular events after myocardial infarction.
    Klungel OH; Heckbert SR; de Boer A; Leufkens HG; Sullivan SD; Fishman PA; Veenstra DL; Psaty BM
    Ann Pharmacother; 2002 May; 36(5):751-7. PubMed ID: 11978147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guideline adherence after ST-segment elevation versus non-ST segment elevation myocardial infarction.
    Somma KA; Bhatt DL; Fonarow GC; Cannon CP; Cox M; Laskey W; Peacock WF; Hernandez AF; Peterson ED; Schwamm L; Saxon LA
    Circ Cardiovasc Qual Outcomes; 2012 Sep; 5(5):654-61. PubMed ID: 22949493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group.
    Schrott HG; Bittner V; Vittinghoff E; Herrington DM; Hulley S
    JAMA; 1997 Apr 23-30; 277(16):1281-6. PubMed ID: 9109465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings.
    Shehab A; Al-Rasadi K; Arafah M; Al-Hinai AT; Al Mahmeed W; Bhagavathula AS; Al Tamimi O; Al Herz S; Al Anazi F; Al Nemer K; Metwally O; Alkhadra A; Fakhry M; Elghetany H; Medani AR; Yusufali AH; Al Jassim O; Al Hallaq O; Baslaib FOAS; Alawadhi M; Amin H; Al-Hashmi K; Oulhaj A
    Curr Vasc Pharmacol; 2018; 16(4):368-375. PubMed ID: 28677510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective analysis of hyperlipidemia management in a transplant population.
    Schonder KS; McKaveney TP; Lynch KJ
    Pharmacotherapy; 2005 Jul; 25(7):918-23. PubMed ID: 16006270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary management of hyperlipidemia in women.
    Mosca LJ
    J Womens Health Gend Based Med; 2002 Jun; 11(5):423-32. PubMed ID: 12165159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns and effectiveness of lipid-lowering therapies in a managed care environment.
    Meyer JW; Schultz JS; O'Donnell JC; Patel PA; Sasane RM
    Value Health; 2005; 8(5):601-12. PubMed ID: 16176498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing hyperlipidemia: current and future roles of HMG-CoA reductase inhibitors.
    Lopez LM
    Am J Health Syst Pharm; 2002 Jun; 59(12):1173-9; quiz 1180-2. PubMed ID: 12073858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gender disparities in lipid-lowering therapy among veterans with diabetes.
    Vimalananda VG; Miller DR; Palnati M; Christiansen CL; Fincke BG
    Womens Health Issues; 2011; 21(4 Suppl):S176-81. PubMed ID: 21724138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.